Melek Tutku Kaçar Şahin

Melek Tutku Kaçar Şahin

Auto-generated profile, based on publicly available information

Melek Tutku Kaçar Şahin

Department of Infectious Diseases and Clinical Microbiology, Viranşehir State Hospital, Şanlıurfa, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Flora the Journal of Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Closed access
MKMelek Tutku Kaçar
Melek Tutku Kaçar
ÖYÖmer Faruk Yardımcı
Ömer Faruk Yardımcı
FKFerit Kuscu
Ferit Kuscu
BKBehice Kurtaran
Behice Kurtaran
ACAslıhan Candevir
Aslıhan Candevir
YTYeşim Taşova
Yeşim Taşova

26 May 2026 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
DEDamla Ertürk
Damla Ertürk
MKMelek Tutku Kaçar-Şahin
Melek Tutku Kaçar-Şahin
SDSümeyra Demir
Sümeyra Demir
ACAslıhan Candevir
Aslıhan Candevir
SKSüheyla Kömür
Süheyla Kömür
YTYeşim Taşova
Yeşim Taşova
Objectives: Nontuberculous mycobacteria (NTM) are emerging opportunistic pathogens with an increasing global incidence. However, epidemiological data and treatment outcomes remain limited in Türkiye. This study aimed to evaluate the clinical characteristics, species distribution, and treatment outcomes of NTM infections in a tertiary center in Türkiye. Materials and Methods: A retrospective analysis was conducted of patients diagnosed with NTM infection between 2021 and 2025 in the Department of Infectious Diseases and Clinical Microbiology. The diagnosis was established according to the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria. Demographic characteristics, risk factors, radiological findings, microbiological profiles, antimicrobial susceptibility patterns, treatment regimens, and clinical outcomes were analyzed. Results: Fourteen patients were included in the study. The mean age was 50.1 ± 13.8 years, and nine patients were male. Underlying risk factors were present in eight patients, including human immunodeficiency virus (HIV) infection (n = 4), malignancy (n = 3), bronchiectasis (n = 1), and chronic obstructive pulmonary disease (COPD) (n = 1). The most frequently identified species were Mycobacterium kansasii (n = 5) and Mycobacterium abscessus (n = 5), followed by Mycobacterium avium, Mycobacterium simiae, Mycobacterium gordonae, and Mycobacterium lentiflavum (n = 1 each). Pulmonary involvement was observed in 10 patients, with nodular lesions in nine and bronchiectasis in five. Among isolates with available antimicrobial susceptibility results (n = 13), susceptibility to clarithromycin, moxifloxacin, linezolid, and amikacin was observed in 12 isolates, whereas resistance was most frequently detected to ciprofloxacin (n = 10) and trimethoprim-sulfamethoxazole (n = 9). Of the 12 patients who initiated treatment, complete clinical response was achieved in nine and partial response in one; two patients with malignancy died before treatment initiation. Conclusion: M. kansasii and M. abscessus were the most frequently identified NTM species in this cohort. Favorable treatment outcomes were observed when therapy was guided by antimicrobial susceptibility results. Species-level identification and susceptibility testing are essential for optimal disease management and strengthening diagnostic capacity. Keywords: Nontuberculous mycobacteria, Mycobacterium kansasii, Mycobacterium abscessus, antimicrobial susceptibility, pulmonary infection, HIV

23 July 2025 in Hepatitis Monthly
Verified
Journal Article
Open access
MŞMelek Tutku Kaçar Şahin
Melek Tutku Kaçar Şahin
MBMuhammed Burak Bereketoğlu
Muhammed Burak Bereketoğlu
HDHamide Doğan
Hamide Doğan
MKMeryem Kose
Meryem Kose
FKFerit Kuscu
Ferit Kuscu
ACAslıhan Candevir
Aslıhan Candevir
Background: Although vaccination programs have significantly reduced the incidence of hepatitis B, chronic infection with the hepatitis B virus (HBV) continues to be a major contributor to liver-related morbidity and mortality. Among available therapeutic outcomes, the clearance of hepatitis B surface antigen (HBsAg) is considered the most favorable endpoint. Objectives: This study aims to evaluate genetic variations in the promoter region of the interferon gamma (IFN-γ)-inducible protein-10 (IP-10) gene — an important chemokine involved in inflammatory responses — which may play a role in the loss of HBsAg during chronic HBV infection. Methods: This research was designed as a single-center case-control study. The study included 60 patients with documented HBsAg loss, retrospectively identified from a cohort of 1,950 chronic hepatitis B patients who were followed at the Infectious Diseases and Clinical Microbiology outpatient clinic of Cukurova University Hospital between 2005 and 2022. A control group of 60 patients who remained HBsAg positive was also included. Peripheral blood samples were collected from all participants, and deoxyribonucleic acid (DNA) was extracted to analyze IP-10 gene polymorphisms. The target gene region was amplified using polymerase chain reaction (PCR), followed by Sanger sequencing. Based on data from the Genome-Wide Association Studies (GWAS) database and published literature, three variants located within the IP-10 promoter, exon 1, intron 1, and exon 2 regions were selected for analysis. The resulting sequence data (in .ab1 format) were analyzed using the CLC Genomics Workbench 24 software. Results: Between 2005 and 2022, the rate of HBsAg loss was calculated as 5.33%. The average age at which HBsAg loss occurred was 53.2 ± 11.3 years, and 85% of the individuals experienced this loss after the age of 40. When comparing the case and control groups, no statistically significant differences were found in terms of gender, current age, age at diagnosis, Body Mass Index, alcohol use, or smoking habits (P > 0.05). Three polymorphisms — c.-135C>T (rs56061981), c.85C>T (rs11548618), and c.83T>G — were detected within the promoter and exon 2 regions of the IP-10 gene. Analysis of genotype and allele distributions revealed no significant differences between the two groups for any of these variants (P > 0.05). Conclusions: Our findings suggest that the c.-135C>T, c.85C>T, and c.83T>G polymorphisms within the IP-10 gene region are not associated with HBsAg loss and therefore may not serve as reliable predictive markers.

9 December 2022 in Flora the Journal of Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Closed access
DEDamla Ertürk
Damla Ertürk
FKFerit Kuscu
Ferit Kuscu
MŞMelek Tutku Kaçar Şahin
Melek Tutku Kaçar Şahin
AİAyşe Seza İnal
Ayşe Seza İnal
ACAslıhan Candevir
Aslıhan Candevir
YTYeşim Taşova
Yeşim Taşova